Dr. Samuel Ray Denmeade, MD

Dr. Denmeade practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Denmeade's NPI, 1225073075, was assigned on June 17, 2006. Dr. Denmeade graduated from Columbia University College of Physicians and Surgeons in 1989. Dr. Denmeade holds Maryland license D44576.

Dr. Denmeade's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Denmeade's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Denmeade is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Denmeade to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denmeade practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Denmeade's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Denmeade is licensed in Maryland.

CMS data shows 615 Medicare services from Dr. Denmeade across 5 procedure codes in 2024, for 157 Medicare patients. Medicare paid $40,710 for them.

CMS counts 157 Medicare patients who saw Dr. Denmeade in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have cancer, and 74% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Denmeade's median patient age at 75, with 6% women.

In 2024, Dr. Denmeade wrote 717 Medicare Part D claims for 68 patients. 93% of them were for generic drugs. CMS names the drug for 578 of them, across 8 drugs with 11 or more claims each, at $785,612 in total drug cost. In 2023, CMS named 330 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Denmeade for performance year 2024, reported as part of a group. CMS lists Dr. Denmeade as offering telehealth.

Dmand AI links 121 papers to Dr. Denmeade, published from 2005 to 2025. 2019 was the busiest year, with 11. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Prostate-Specific Antigen. Dr. Denmeade has published most often in Prostate. Dr. Denmeade's most frequent co-authors are Michael Anthony Carducci, MD, Mario Eisenberger, MD and Channing Paller, MD.

Dmand AI links Dr. Denmeade to 9 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and COVID-19. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 8.

CMS Open Payments shows 20 general payments to Dr. Denmeade from 6 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 59% of the total. Sanofi and Genzyme US Companies paid the most, $1,202.

Dr. Denmeade graduated from Columbia University College of Physicians and Surgeons in 1989.